Professional Advisory Services Inc. Has $20.70 Million Stake in Novartis AG (NVS)

Professional Advisory Services Inc. lowered its position in shares of Novartis AG (NYSE:NVS) by 0.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 215,321 shares of the company’s stock after selling 1,451 shares during the quarter. Novartis makes up approximately 4.2% of Professional Advisory Services Inc.’s holdings, making the stock its 2nd biggest holding. Professional Advisory Services Inc.’s holdings in Novartis were worth $20,701,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Independence Bank of Kentucky increased its position in Novartis by 50.0% in the 1st quarter. Independence Bank of Kentucky now owns 450 shares of the company’s stock valued at $43,000 after acquiring an additional 150 shares in the last quarter. SG Americas Securities LLC increased its position in Novartis by 18.2% in the 1st quarter. SG Americas Securities LLC now owns 22,845 shares of the company’s stock valued at $2,196,000 after acquiring an additional 3,516 shares in the last quarter. Norris Perne & French LLP MI increased its position in Novartis by 2.4% in the 1st quarter. Norris Perne & French LLP MI now owns 135,157 shares of the company’s stock valued at $12,994,000 after acquiring an additional 3,135 shares in the last quarter. CNB Bank increased its position in Novartis by 6.3% in the 1st quarter. CNB Bank now owns 6,941 shares of the company’s stock valued at $667,000 after acquiring an additional 412 shares in the last quarter. Finally, Atlas Capital Advisors LLC increased its position in Novartis by 67.5% in the 1st quarter. Atlas Capital Advisors LLC now owns 10,716 shares of the company’s stock valued at $1,030,000 after acquiring an additional 4,317 shares in the last quarter. Institutional investors and hedge funds own 11.66% of the company’s stock.

NVS has been the subject of several research reports. Liberum Capital upgraded shares of Novartis from a “hold” rating to a “buy” rating in a research report on Thursday, April 25th. Guggenheim raised shares of Novartis from a “neutral” rating to a “buy” rating and set a $79.16 target price on the stock in a research note on Wednesday, April 24th. JPMorgan Chase & Co. reaffirmed a “sell” rating on shares of Novartis in a research note on Tuesday, January 29th. Zacks Investment Research lowered shares of Novartis from a “hold” rating to a “strong sell” rating in a research note on Thursday, April 11th. Finally, Morgan Stanley lowered shares of Novartis from an “equal weight” rating to an “underweight” rating and raised their target price for the company from $82.50 to $82.52 in a research note on Wednesday, April 10th. Five analysts have rated the stock with a sell rating, four have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $87.57.

Shares of NYSE NVS traded up $1.52 during mid-day trading on Wednesday, hitting $83.91. The company’s stock had a trading volume of 2,351,425 shares, compared to its average volume of 2,545,515. The firm has a market capitalization of $191.27 billion, a PE ratio of 16.49, a price-to-earnings-growth ratio of 1.99 and a beta of 0.66. The company has a current ratio of 0.93, a quick ratio of 0.83 and a debt-to-equity ratio of 0.48. Novartis AG has a one year low of $63.60 and a one year high of $85.08.

Novartis (NYSE:NVS) last released its quarterly earnings data on Wednesday, April 24th. The company reported $1.21 earnings per share for the quarter, topping the consensus estimate of $1.11 by $0.10. Novartis had a net margin of 24.55% and a return on equity of 16.75%. The business had revenue of $11.11 billion for the quarter, compared to analyst estimates of $11.76 billion. During the same quarter last year, the firm earned $1.28 EPS. Novartis’s quarterly revenue was up 1.7% compared to the same quarter last year. As a group, equities research analysts anticipate that Novartis AG will post 5 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Professional Advisory Services Inc. Has $20.70 Million Stake in Novartis AG (NVS)” was first posted by Sundance Herald and is owned by of Sundance Herald. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://sundanceherald.com/2019/05/22/professional-advisory-services-inc-sells-1451-shares-of-novartis-ag-nvs.html.

Novartis Profile

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.

Recommended Story: When is a capital gain realized?

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply